Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide in newly diagnosed glioblastoma (CORE)
NCT00813943Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Mar 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cilengitide in glioblastoma (GBM) (3 arms), sponsored by EMD Serono. Primary endpoint: Overall Survival. Started Mar 2009; status: completed.
02
Drugs
cilengitide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00813943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813943.